Utama › Leukemia Sel-B
Kajian klinikal Leukemia Sel-B sedang mengambil peserta di AS
17 kajian untuk Leukemia Sel-B sedang mengambil peserta di lokasi seluruh Amerika Syarikat.
Bandar dengan paling banyak kajian
- Houston, TX7 kajian
- Washington, DC5 kajian
- Dallas, TX5 kajian
- Columbus, OH4 kajian
- Portland, OR4 kajian
- Philadelphia, PA3 kajian
- Spokane, WA3 kajian
- Boston, MA3 kajian
- New York City, NY3 kajian
- San Diego, CA3 kajian
- Clifton, NJ3 kajian
- Charlotte, NC3 kajian
- Louisville, KY3 kajian
- Edison, NJ3 kajian
- Pittsburgh, PA3 kajian
- Chicago, IL3 kajian
- Denver, CO3 kajian
Mengikut negeri
- California7 kajian
- Colorado3 kajian
- Florida3 kajian
- Illinois4 kajian
- Kansas3 kajian
- Kentucky3 kajian
- Maryland5 kajian
- Massachusetts3 kajian
- Minnesota3 kajian
- New Jersey4 kajian
- New York4 kajian
- North Carolina5 kajian
- Ohio7 kajian
- Oregon4 kajian
- Pennsylvania5 kajian
- Texas12 kajian
- Washington5 kajian
Kajian yang dikemas kini baru-baru ini
Teks kajian rasmi (Bahasa Inggeris)
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT06542250CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
Mengambil pesertaFasa 1/2
Umur 3 hingga 39 · Semua jantina · Dikemas kini 30 Sep 2026 · NCT05442515Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Mengambil pesertaKajian pemerhatian
Umur 18 hingga 110 · Semua jantina · Dikemas kini 28 Sep 2026 · NCT00923507Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
Mengambil pesertaFasa 4
Umur 18 hingga 130 · Semua jantina · Dikemas kini 24 Sep 2026 · NCT06651970Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT04728893Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)
Mengambil pesertaFasa 1
Sehingga umur 75 · Semua jantina · Dikemas kini 16 Sep 2026 · NCT06345027A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Sep 2026 · NCT06564038Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
Mengambil pesertaFasa 3
Umur 18 hingga 18 · Semua jantina · Dikemas kini 8 Sep 2026 · NCT07509151Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)
Mengambil pesertaFasa 1
12 Months – 25 Years · Semua jantina · Dikemas kini 4 Sep 2026 · NCT05010564Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
Mengambil pesertaFasa 2
Umur 7 hingga 25 · Semua jantina · Dikemas kini 19 Ogo 2026 · NCT05082519A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Ogo 2026 · NCT05254743ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 11 Ogo 2026 · NCT07342478A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 31 Jul 2026 · NCT06708897The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Mengambil pesertaFasa 1/2
Umur 12 hingga 95 · Semua jantina · Dikemas kini 15 Apr 2026 · NCT04329728A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Mengambil pesertaFasa 2
Umur 18 hingga 66 · Semua jantina · Dikemas kini 17 Mac 2026 · NCT06859424A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab
Mengambil pesertaKajian pemerhatian
Umur 1 hingga 23 · Semua jantina · Dikemas kini 25 Feb 2026 · NCT07422337Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 22 Jan 2026 · NCT06357754Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.